News

PHEXCOM

Solution BY Communication

Call：+86 021-55807300

Position：Home > News >

Cytiva tasked with COVID-19 vaccine work as part of $31M U.S. government grant

With the U.S. working at a rapid clip to scale capacity for a range of COVID-19 vaccines and therapeutics, stateside companies are snagging big down payments on the taxpayers' dime. Now, the governme
2020/10/13
Hey investors, COVID-19 vaccine manufacturing partner Emergent won't suffer from AZ, J&J trial holds: analysts

Shares of Emergent BioSolutions have been on a roller coaster of late, plummeting last month when customer AstraZeneca had to put its COVID-19 vaccine trial on hold, then taking a beating again yeste
2020/10/13
J&J's immunology meds Stelara, Tremfya posted big revenue gains, but pricing is slipping: analyst

Johnson & Johnson touted solid growth for its immunology meds Stelara and Tremfya in its latest quarterly results,butBernstein analysts are spotlighting steep net pricing declines for the meds am
2020/10/12
No need to panic about COVID-19 trial halts, FDA chief says. They show the system is working

Headlines about COVID-19 vaccine and drug trial pauses may ring alarm bells for millions of people watching their progress, but FDA Commissioner Stephen Hahn, M.D., has another point of view. The bre
2020/10/12
Regeneron, in the thick of COVID-19 fight, snags historic FDA approval for Ebola treatment

With the worldfocused on the fight against COVID-19, the scientific community just scored a big win against the Ebola virus. The FDA has approved the first treatment—Inmazebfrom Regeneron—to treatZai
2020/10/10
Merck, plagued by limited supply of bladder cancer drug, will build new facility to triple production

During its years as sole producer of a difficult-to-make cancer med in high demand, Merck & Co.'s limited capacity has hamstrung its efforts to get the drug into patients' hands.Now, Merckis putt
2020/10/10
ESMO: Bristol Myers' Opdivo racks up GI cancer data for 2 potentially practice-changing FDA nods

Gastrointestinal cancers are stubborn, as plenty of oncology drugmakers know. But Bristol Myers Squibb’s immunotherapy Opdivo has broken through with a couple of potentially practice-changing trials
2020/9/25
AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push

Unlike some other manufacturers, Samsung Biologics has enjoyed a revenue boost from the novel coronavirus pandemic, and it's accelerating its expansion plans to match. With a $2 billion "super plant"
2020/9/25
Former Biogen CFO Capello scores $2.6M payment plus full severance benefits on his way out

After bringing ina new CFO this summer—and as it navigates a turbulent stretch—Biogenis givingformerchief finance officer Jeff Capello a multimillion-dollar cash paymentplus other severance benefits.
2020/9/24
Bristol, Amgen, Teva CEOs among execs to testify at House drug pricing hearings next week

After thelate Rep. Elijah Cummingslaunched a drug pricing probe of some of the industry's largest players last January, six pharmaceutical execs are set to head to Washington next week forhearings at
2020/9/24

Excipients